Showing 3941-3950 of 4165 results for "".
- NeurOptics Launches Virtual Pupillometry Education Platformhttps://modernod.com/news/neuroptics-launches-virtual-pupillometry-education-platform/2478910/NeurOptics has launched its Pupillometry Education Symposiums platform, which includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the Neurological Pupil index (NPi) play in the assessment and screening of patients at risk of ne
- Topcon Announces US Launch of the Harmony Glaucoma Modulehttps://modernod.com/news/topcon-announces-us-launch-of-the-harmony-glaucoma-module/2478906/Topcon Healthcare announced it has launched its new Glaucoma Module feature for the Harmony Clinical Data Management Solution. The new Glaucoma Module provides eye care professionals easy access to the information needed to diagnose and manage glaucoma on a single screen. The Hood Dashboar
- Optimo Medical and Ansys Partner Announce Partnership to Improve Surgery Preparationhttps://modernod.com/news/optimo-medical-and-ansys-partner-announce-partnership-to-improve-surgery-preparation/2478904/Optimo Medical and Ansys are incorporating high-fidelity structural simulations with digital twin technology into next-generation surgery preparation, according to a company news release. The collaboration also drives in silico clinical trials of new eye products, with the aim of significantly re
- Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/Ocuphire Pharma announced that it has enrolled the first patients in a phase 2 proof of concept trial, titled VEGA-1, to evaluate a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Over 12 sites representing a majority of the planned clinical sites are activated and recruiting pat
- Gyroscope Therapeutics Announces Positive Interim Data from Phase 1 FOCUS Trial of Investigational Gene Therapy GT005https://modernod.com/news/gyroscope-therapeutics-announces-positive-interim-data-from-phase-1-focus-trial-of-investigational-gene-therapy-gt005/2478865/Gyroscope Therapeutics announced positive interim safety, protein expression and biomarker data from the ongoing open-label phase 1/2 FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Inte
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/Lytenava (Bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-reports-final-visit-for-last-patient-in-open-label-safety-study-for-ons-5010-lytenava-bevacizumab-vikg/2478861/Outlook Therapeutics announced that the last patient completed their final visit for the ongoing open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases (NORSE THREE). Two of the three planned clinical trials for the ONS-5010/Lytenava wet age
- Insurer Ducks Virus Coverage Claims From NJ Eye Practicehttps://modernod.com/news/insurer-ducks-virus-coverage-claims-from-nj-eye-practice/2478857/A proposed class action lawsuit from an eye clinic in New Jersey, which was seeking to recoup losses it incurred during the COVID-19 pandemic from an insurance company, was struck down by a New Jersey federal judge, according to a LAW360
- Surface Ophthalmics Announces First Patient Dosed in Phase 2 Trial for SURF-200 for Acute Dry Eyehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-phase-2-trial-for-surf-200-for-acute-dry-eye/2478833/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye. In this dose-ranging study, SURF-200 will be studied in two different low concen
- Surface Ophthalmics Announces First Patient Dosed in Head-to-Head Phase 2 Trial for SURF-100 for Chronic Dry Eye Diseasehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-head-to-head-phase-2-trial-for-surf-100-for-chronic-dry-eye-disease/2478802/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) for the treatment of chronic dry eye disease. SURF-100 utilizes a new an
- GenSight Biologics Announces Publication of Results from Lumevoq RESCUE Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-rescue-phase-3-trial/2478755/GenSight Biologics announced that Ophthalmology has published results from the RESCUE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper, published in the January issue under the title, “Efficacy and safety